Darrell Tan

MD, PhD, FRCPC

Scientist, Li Ka Shing Knowledge Institute

Biography

Dr. Tan is an infectious diseases physician, clinician-scientist and CIHR New Investigator whose research focuses on clinical trials in HIV prevention and HIV/STI co-infection. As Director of the University of Toronto Clinical Research Unit on HIV Prevention and co-leader of the CIHR Canadian HIV Trials Network Biomedical Prevention Working Group, he is leading multiple efforts to optimize the implementation of HIV pre- and post-exposure prophylaxis (PrEP and PEP) in Canada. These include Canada’s first demonstration project of daily oral TDF/FTC-based PrEP in Toronto MSM, the development of national Clinical Practice Guidelines on PEP & PrEP use, exploration of the relationship between syndemic health problems and clinical outcomes of PEP & PrEP, studies of nurse-led PEP & PrEP, and evaluations of novel antiretroviral PEP regimens.

Additional research interests are in the interaction between HIV and common co-infections such as herpes simplex virus type 2 (HSV-2) and syphilis, and the role of systemic inflammation in driving clinical outcomes in people living with HIV. He is also Co-PI on two CIHR-supported multicentre RCTs including the a trial of anti-herpes medication for attenuating HIV disease progression, and a trial of enhanced syphilis screening in HIV-positive men.

Recent Publications

  1. Wilton, J, Kain, T, Fowler, S, Hart, TA, Grennan, T, Maxwell, J et al.. Use of an HIV-risk screening tool to identify optimal candidates for PrEP scale-up among men who have sex with men in Toronto, Canada: disconnect between objective and subjective HIV risk. J Int AIDS Soc. 2016;19 (1):20777. . PubMed PMID:27265490 PubMed Central PMC4911732.
  2. Grewal, R, Allen, VG, Gardner, S, Moravan, V, Tan, DH, Raboud, J et al.. Serosorting and recreational drug use are risk factors for diagnosis of genital infection with chlamydia and gonorrhoea among HIV-positive men who have sex with men: results from a clinical cohort in Ontario, Canada. Sex Transm Infect. 2016; :. doi: 10.1136/sextrans-2015-052500. PubMed PMID:27154185 .
  3. Burchell, AN, Allen, VG, Grewal, R, MacPherson, PA, Rachlis, A, Walmsley, S et al.. Enhanced syphilis screening among HIV-positive men (ESSAHM): a study protocol for a clinic-randomized trial with stepped wedge design. Implement Sci. 2016;11 :8. doi: 10.1186/s13012-016-0371-0. PubMed PMID:26772390 PubMed Central PMC4715363.
  4. Tan, DH, Szadkowski, L, Raboud, J, Yi, TJ, Shannon, B, Kaul, R et al.. Effect of Intercurrent Infections and Vaccinations on Immune and Inflammatory Biomarkers Among Human Immunodeficiency Virus-Infected Adults on Suppressive Antiretroviral Therapy. Open Forum Infect Dis. 2015;2 (2):ofv036. Epub 2015/3/09. doi: 10.1093/ofid/ofv036. PubMed PMID:26380337 PubMed Central PMC4567101.
  5. Burchell, AN, Allen, VG, Gardner, SL, Moravan, V, Tan, DH, Grewal, R et al.. High incidence of diagnosis with syphilis co-infection among men who have sex with men in an HIV cohort in Ontario, Canada. BMC Infect. Dis. 2015;15 :356. doi: 10.1186/s12879-015-1098-2. PubMed PMID:26289937 PubMed Central PMC4546079.
  6. Yoong, D, Naccarato, M, Sharma, M, Wilton, J, Senn, H, Tan, DH et al.. Preparing for pre-exposure prophylaxis: perceptions and readiness of Canadian pharmacists for the implementation of HIV pre-exposure prophylaxis. Int J STD AIDS. 2016;27 (8):608-16. doi: 10.1177/0956462415589896. PubMed PMID:26025254 .
  7. Wilton, J, Senn, H, Sharma, M, Tan, DH. Pre-exposure prophylaxis for sexually-acquired HIV risk management: a review. HIV AIDS (Auckl). 2015;7 :125-36. Epub 2015/4/28. doi: 10.2147/HIV.S50025. PubMed PMID:25987851 PubMed Central PMC4422285.
  8. Klein, MB, Young, J, Dunn, D, Ledergerber, B, Sabin, C, Cozzi-Lepri, A et al.. The effects of HIV-1 subtype and ethnicity on the rate of CD4 cell count decline in patients naive to antiretroviral therapy: a Canadian-European collaborative retrospective cohort study. CMAJ Open. 2014;2 (4):E318-29. Epub 2014/10/1. doi: 10.9778/cmajo.20140017. PubMed PMID:25485259 PubMed Central PMC4251518.
  9. Tan, DH, Raboud, JM, Szadkowski, L, Yi, TJ, Shannon, B, Kaul, R et al.. Herpes simplex virus type 2 serostatus is not associated with inflammatory or metabolic markers in antiretroviral therapy-treated HIV. AIDS Res. Hum. Retroviruses. 2015;31 (3):276-81. doi: 10.1089/AID.2014.0183. PubMed PMID:25399537 PubMed Central PMC4348084.
  10. Taras, J, Arbess, G, Owen, J, Guiang, CB, Tan, DH. Acceptability of bone antiresorptive therapy among HIV-infected adults at different stages of antiretroviral therapy. Patient Prefer Adherence. 2014;8 :1311-6. Epub 2014/9/24. doi: 10.2147/PPA.S67090. PubMed PMID:25284989 PubMed Central PMC4181646.
Search PubMed

Affiliations & Other Activities

  • Clinician-Scientist, Department of Medicine, St. Michael’s Hospital
  • Assistant Professor, University of Toronto Department of Medicine
  • Assistant Professor, University of Toronto Institute of Health Policy, Management & Evaluation
  • Director, University of Toronto HIV Prevention Clinical Research Unit
  • Affiliate Scientist, Toronto General Research Institute
  • Centre for Research in Inner City Health